Thus, the immunosensor technique, taking advantage of monoclonal antibodies against specific HMGB1 isoforms to detect HMGB1 in plasma/serum could be a prospective routine method (in combination with other methods and biomarkers) for monitoring the occurrence, treatment success, and survival prediction of patients with inflammation-mediated diseases, including COVID-19. This evidence concerns the gene HMGB1 and COVID-19.